ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, reported on Thursday positive early results from two late-stage trials testing its two-drug regimen in patients new to HIV treatment relative to a three-drug regimen.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,